HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Reassessing the NTCTCS Staging Systems for Differentiated Thyroid Cancer, Including Age at Diagnosis.

AbstractBACKGROUND:
Thyroid cancer is unique for having age as a staging variable. Recently, the commonly used age cut-point of 45 years has been questioned.
OBJECTIVE:
This study assessed alternate staging systems on the outcome of overall survival, and compared these with current National Thyroid Cancer Treatment Cooperative Study (NTCTCS) staging systems for papillary and follicular thyroid cancer.
METHODS:
A total of 4721 patients with differentiated thyroid cancer were assessed. Five potential alternate staging systems were generated at age cut-points in five-year increments from 35 to 70 years, and tested for model discrimination (Harrell's C-statistic) and calibration (R(2)). The best five models for papillary and follicular cancer were further tested with bootstrap resampling and significance testing for discrimination.
RESULTS:
The best five alternate papillary cancer systems had age cut-points of 45-50 years, with the highest scoring model using 50 years. No significant difference in C-statistic was found between the best alternate and current NTCTCS systems (p = 0.200). The best five alternate follicular cancer systems had age cut-points of 50-55 years, with the highest scoring model using 50 years. All five best alternate staging systems performed better compared with the current system (p = 0.003-0.035). There was no significant difference in discrimination between the best alternate system (cut-point age 50 years) and the best system of cut-point age 45 years (p = 0.197).
CONCLUSIONS:
No alternate papillary cancer systems assessed were significantly better than the current system. New alternate staging systems for follicular cancer appear to be better than the current NTCTCS system, although they require external validation.
AuthorsDonald S A McLeod, Jacqueline Jonklaas, James D Brierley, Kenneth B Ain, David S Cooper, Henry G Fein, Bryan R Haugen, Paul W Ladenson, James Magner, Douglas S Ross, Monica C Skarulis, David L Steward, Mingzhao Xing, Danielle R Litofsky, Harry R Maxon, Steven I Sherman
JournalThyroid : official journal of the American Thyroid Association (Thyroid) Vol. 25 Issue 10 Pg. 1097-105 (Oct 2015) ISSN: 1557-9077 [Electronic] United States
PMID26203804 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Topics
  • Adenocarcinoma, Follicular (pathology)
  • Adult
  • Age Factors
  • Age of Onset
  • Aged
  • Carcinoma, Papillary (pathology)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Prognosis
  • Thyroid Gland (pathology)
  • Thyroid Neoplasms (pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: